BridgeBio Oncology Therapeutics logo

BridgeBio Oncology Therapeutics

BBOT | NASDAQ
Chart Builder DCF Calculator
$1.98
-$0.16 (-7.48%)
At close: Nov 16, 2026, 4:00 PM ET
$2.01
+$0.03 (+1.52%)
After-hours: Nov 16, 2026, 7:00 PM ET
-7.48%

Rating

Updated: Nov 16, 2026
25.2
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #923/1021 (Top 90%)

Key Statistics

Market Data

Market Cap $158.9M
1D Range
1.98 2.23
52W Range
1.98 13.73

Valuation (TTM)

PE 0
PB 0.54
EV/EBITDA 0.18

Valuation (NTM)

Forward PE N/A
Forward PEG 0.00
Price Target $20.00
Loading financial charts...

Profile

BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinosit...

Sector Healthcare
Industry Biotechnology
Employees 88
IPO Date Aug 12, 2025
Website bbotx.com
Fiscal Year January - December

Latest News

BridgeBio Oncology Therapeutics, Inc. (BBOT) Discusses Clinical Data Updates for BBO-8520, BBO-11818, and BBO-10203 Transcript

10 months ago · seekingalpha.com

BridgeBio Oncology Therapeutics, Inc. (BBOT) Discusses Clinical Data Updates for BBO-8520, BBO-11818, and BBO-10203 Transcript

Analyst Summary

# of Analysts
10
Consensus
Buy
Price Target
$20.00
Upside
+910.10%
Buy (10)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.